Naproxen is one of the most common over the counter and prescription pain relievers in the country, sold under its generic name and under brand names as both a tablet and a sodium salt formulation. Because it shows up in so many medicine cabinets, it is also one of the medications employees ask about most often after a workplace drug screen comes back presumptive positive. This post explains what naproxen actually is, whether it is a controlled substance, what the published cross reactivity evidence says about immunoassay screens, and how confirmation testing and medical review officer documentation resolve a disputed result.
What naproxen is and how it is classified
Naproxen is a nonsteroidal anti inflammatory drug, or NSAID, in the same broad drug class as ibuprofen. It works by blocking cyclooxygenase enzymes to reduce pain, fever, and inflammation. It is sold without a prescription in lower dose sodium salt form and by prescription at higher doses for arthritis and other chronic pain conditions. The federal drug labeling for naproxen sodium products, maintained through the National Library of Medicine's DailyMed database, describes it as an over the counter analgesic, not a scheduled drug. Naproxen is not listed on the Drug Enforcement Administration's controlled substance schedules, so a positive finding tied to naproxen carries none of the regulatory weight that a controlled substance would in a workplace testing program. You can review an example of the current federal labeling for a naproxen sodium product directly on DailyMed.
Which panel classes could even be affected
Naproxen is not a target analyte on any standard drug test panel. No 5 panel, 10 panel, or 12 panel immunoassay is built to detect naproxen itself, and no manufacturer markets a strip or cup calibrated to find it. The question employers and employees actually mean to ask is narrower: can naproxen's chemical structure cross react with the antibodies used in a THC (cannabinoid) immunoassay or a barbiturate immunoassay, producing a false signal for a different drug class entirely. That is a real phenomenon in immunoassay chemistry generally, and it is the mechanism behind most medication related false positives, not an effect limited to naproxen.
What the published cross reactivity evidence actually says
The clearest primary source on this specific question is a peer reviewed clinical toxicology review published through the National Library of Medicine's PubMed Central archive. The article, which catalogs substances reported to interfere with urine immunoassays, lists naproxen alongside ibuprofen among the agents noted in occasional case reports to produce false positive results on cannabinoid screens, and separately notes that both ibuprofen and naproxen have been associated with false positive results on barbiturate immunoassays in some assay formats. Read the full discussion, including the citations behind it, in Buyer Beware: Pitfalls in Toxicology Laboratory Testing.
It is important to describe that evidence accurately rather than overstate it. The same review is explicit that the barbiturate immunoassay generally performs with good sensitivity for the barbiturates that are actually prescribed, and that cross reactivity reports involving NSAIDs are occasional, not a routine or reproducible event across every assay platform on the market. Cross reactivity in an immunoassay depends on the specific antibody formulation a manufacturer uses, the cutoff concentration, and the sample matrix, so a result reported with one assay design does not automatically apply to every cup, dip card, or laboratory analyzer in use today. Where no published study ties a specific assay brand or lot to naproxen interference, the honest statement is that the evidence is limited and assay specific, not that naproxen will never affect a screen or that it always does.
| Panel class | Is naproxen a target analyte | Reported cross reactivity |
|---|---|---|
| THC or cannabinoids | No | Occasional case reports in older literature, assay specific, not reproduced across all platforms |
| Barbiturates | No | Occasional case reports, immunoassay still described as generally sensitive for prescribed barbiturates |
| Amphetamines, cocaine, opiates, PCP | No | No published cross reactivity identified for naproxen |
How GC/MS or LC/MS confirmation resolves a presumptive result
An immunoassay screen is a presumptive test. It is fast and inexpensive, but it works by detecting a class of similarly shaped molecules rather than one exact substance, which is exactly why cross reactivity with unrelated medications can happen at all. Any presumptive positive on a cannabinoid or barbiturate screen that matters for employment, legal, or regulated testing purposes should be sent for confirmation using gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS), methods that identify the exact molecule rather than a structural family. The same PubMed Central review notes that GC/MS is both more sensitive and more specific than immunoassay screening, and recommends confirmation testing whenever a result carries forensic or employment consequences. If a donor took naproxen and nothing else, a properly run GC/MS or LC/MS confirmation for cannabinoids or barbiturates should come back negative, because the confirmation method targets THC metabolites or specific barbiturate compounds, not NSAIDs.
The medical review officer review and documentation step
For testing conducted under federal Department of Transportation rules, no result is reported to an employer as positive until a medical review officer (MRO) has reviewed it under the process set out in 49 CFR Part 40. The MRO contacts the donor, asks about prescription and over the counter medications taken around the time of the test, and reviews any documentation the donor provides. A verified negative confirmation closes the matter. Even where a presumptive screen flagged, a negative GC/MS or LC/MS confirmation means the laboratory reports the specimen as negative, and the MRO process exists specifically to catch and resolve exactly this kind of medication related question before any adverse action is considered. The full MRO verification process, including how donors are interviewed and how documentation is handled, is laid out in 49 CFR Part 40, Subpart G on the Electronic Code of Federal Regulations. Employers who are not DOT regulated generally still rely on similar MRO review or a comparable toxicologist led process; the underlying principle, that a single immunoassay screen is not a final result, applies broadly across federal workplace testing programs described by the Substance Abuse and Mental Health Services Administration's drug free workplace resources.
What employers should do with a disputed result
An employee who reports taking naproxen before a positive cannabinoid or barbiturate screen has raised exactly the kind of question the confirmation and MRO steps exist to answer, not a reason to assume either guilt or innocence. Employers should route the result through confirmation testing and, where applicable, MRO review rather than making a decision off the initial screen alone. Documentation from the employee, such as a pharmacy receipt or a note describing an over the counter purchase, can support the MRO's review but is not itself a verification; the confirmation laboratory result is what resolves the question. Policies and practical steps vary by state and by whether the employer is DOT regulated, so employers with a disputed result should consult the applicable testing regulation and their own counsel rather than relying on a general rule.
Frequently asked questions
Does naproxen show up as a specific drug on a standard panel?
No. No 5 panel, 10 panel, or 12 panel immunoassay is designed to detect naproxen as its own analyte. The only way naproxen enters the conversation is through reported cross reactivity with a different panel class, such as cannabinoids or barbiturates.
Is naproxen a controlled substance?
No. Naproxen is an NSAID sold over the counter and by prescription. It does not appear on the Drug Enforcement Administration's controlled substance schedules, as reflected in its federal drug labeling on DailyMed.
Can naproxen cause a false positive THC result?
Published toxicology literature lists naproxen among NSAIDs noted in occasional case reports to interfere with cannabinoid immunoassays. The evidence is limited and assay specific rather than a routine effect, and a GC/MS or LC/MS confirmation negative for THC metabolites resolves the question. See the discussion in this PubMed Central review.
Can naproxen cause a false positive barbiturate result?
The same published review notes occasional reports of naproxen and ibuprofen associated with false positive barbiturate immunoassay results in some assay formats, while also describing the barbiturate immunoassay as generally sensitive for the barbiturates that are actually prescribed today. Confirmation testing resolves any presumptive finding.
What should an employee do if they tested positive after taking naproxen?
Tell the collector or the medical review officer which medications were taken, including over the counter NSAIDs, and let the confirmation and MRO process run. Do not attempt to explain away a result by any means other than disclosure and documentation.
What should an employer do if an employee disputes a result because of naproxen?
Route the specimen through GC/MS or LC/MS confirmation and, where the testing program requires it, a medical review officer review under 49 CFR Part 40, Subpart G before taking any employment action based on the result.
American Screening Corporation supplies drug test cups, dip cards, and oral fluid tests used in workplace testing programs across the country. Related reading on this site covers the barbiturate panel and its detection windows and how the medical review officer process works in more detail. Employers building or restocking a testing program can browse the current lineup of drug test cups.
This article is general information about drug testing science and procedure, not medical or legal advice. Employers and employees with a specific disputed result should consult the applicable testing regulation, a qualified medical review officer, or their own counsel.
